ADO and B-cell chronic lymphocytic leukemia: Similar effects were observed when exposing CLL cells to fludarabine, where ADO conferred complete protection to CLL cells, although the effect is not fully recapitulated by the A2A agonist, opening to the possibility that in this context ADO should act through both A2A-dependent and -independent mechanisms [2].